

MARKSANS PHARMA LIMITED

Regd. Office: 21st Floor, Lotus Business Park, Off. New Link Road, Andheri (West), Mumbai-400053

ANNUAL AUDITED STANDALONE FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2010 AND UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2010

Rs.in Lacs

Sr. No.	PARTICULARS	For the Quarter ended on		For the year ended on	For the year ended on
		30.6.2010 (UNAUDITED)	30.6.2009 (UNAUDITED)	31st March 10 (AUDITED)	31st March 09 (AUDITED)
1	Income				
a>	Net Sales/ Income from Operations	4,176.51	4,533.47	19,956.21	20,356.11
b>	Other Operating Income	29.40	48.19	160.37	735.05
	Total Income	4,205.91	4,581.66	20,116.58	21,091.16
2	Expenditure				
a>	Increase/Decrease in stock in trade	(249.43)	99.52	1,198.19	(1,060.41)
b>	Consumption of Material & Purchases	3,043.54	3,186.79	13,443.92	14,382.54
c>	Employee Cost	294.94	248.26	1,069.13	1,265.74
d>	Depreciation	245.98	243.24	983.92	972.96
e>	Other Expenditure	354.33	716.76	1,880.92	3,758.39
	Total Expenditure	3,689.36	4,494.57	18,576.08	19,319.22
3	Profit from Operations before other income				
	Interest & Exceptional Items (1-2)	516.55	87.09	1,540.50	1,771.94
4	Other Income	-	-	-	-
5	Profit before Interest & Exceptional item (3+4)	516.55	87.09	1,540.50	1,771.94
6	Interest	395.56	428.47	1,477.83	1,532.86
7	Profit after Interest but before Tax Exceptional items	120.99	(341.38)	62.67	239.08
8	Exceptional items	-	-	-	-
9	Profit/(Loss) from Ordinary activities before Tax (7+8)	120.99	(341.38)	62.67	239.08
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Y	-	3.38	33.69	189.58
11	Net Profit/(loss) from Ordinary activities after tax(9-10)	120.99	(344.76)	28.98	49.50
12	Extraordinary Item- Minority Interest	-	-	-	-
13	Net Profit/ (Loss) for the period (11-12)	120.99	(344.76)	28.98	49.50
14	Paid up Equity Share Capital (Face Value Re.1 each)	3,678.05	3,678.05	3,678.05	3,678.05
15	Reserve Excluding Revaluation Reserve as per				
	Balance sheet of Previous Accounting year	-	-	-	10,881.63
16	a>. Earnings Per Share (Basic & Diluted)	0.03	(0.09)	0.01	0.01
	(before extraordinary items.Rs.)				
	b>. Earnings Per Share(Basic & Diluted)	0.03	(0.09)	0.01	0.01
	(after Extraordinary items- Rs.)				
17	Aggregate of Public Shareholding:				
	- Number of Shares	189,823,694	189,822,361	189,822,361	188,222,361
	- Percentage of Holding	51.61%	51.61%	51.61%	51.17%
18	Promoters and Promoter group Shareholdings	177,983,510	177,983,510	177,983,510	179,583,510
	a>. Pledged/Encumbered				
	- Number of Shares	NIL	NIL	NIL	NIL
	- Percentage of Holding	N.A	N.A	N.A	N.A
	(as a % of the total shareholding of Promoter and Promoter Group)				
	- Percentage of Holding	N.A	N.A	N.A	N.A
	(as a % of the total share capital of the Company)				
	a>. Non-encumbered				
	- Number of Shares	177,983,510	177,983,510	177,983,510	179,583,510
	- Percentage of Holding	100%	100%	100%	100%
	(as a % of the total shareholding of Promoter and Promoter Group)				
	- Percentage of Holding	48.39%	48.39%	48.39%	48.83%
	(as a % of the total share capital of the Company)				

Contd....2 .




Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12.08.2010.
- 2 There were no pending investor complaints at the beginning and end of the quarter. The Company has not received any investors complaint during the quarter.
- 3 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- 4 No Provision have been made during the year for Foreign Exchange Difference account in case of Foreign Currency Convertible Bond. The Management is of the opinion that the determination and crystallisation of liabilities is dependent upon the outcome of uncertain future events or actions, not wholly within the control of the company and therefore the same has been considered as a "Contingnet Liability" as at 30th June,2009.
- 5 The Company is primarily engaged in a single segment business of Manufacturing & Marketing of Pharmaceutical Formulations and Active Pharmaceutical Ingridents and is managed as one entity, for its various activities and is governed by similar set of risk and returns.
- 6 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.
- 7 The Company has issued and allotted 1,333 equity shares of R.1 each on conversion of one FCCB of US\$ 1000/- on 14.04.2010. Accordingly, the issued, subscribed and paid up equity share capital of the company has increased from Rs.36,78,05,871/- to Rs.36,78,07,204/- effective from 14.04.2010.
- 8 The company has on 28th July,2010 entered into a Business Transfer Agreement with Kores(India) Limited for sale and transfer of its Active Pharmaceutical Ingredients (API) business together with its Manufacturing facilities located at plot Nos.A-88 and D-10,MIDC, Kurkumbh, Pune, Maharashtra.
- 9 Statement of Assets and Liabilities.

Particulars	(Rs. In Lakhs)	
	YEAR ENDED	YEAR ENDED
	31.03.2010	31.03.2009
	AUDITED	AUDITED
SHAREHOLDERS FUND:		
(a) Capital	5,028.06	5,028.06
(b) Reserve and Surplus	6,030.79	4,404.88
LOAN FUNDS	35,289.63	31,906.10
FIXED ASSETS	29,414.24	27,895.56
INVESTMENTS	7,761.64	6,755.83
CURRENT ASSETS, LOANS AND ADVANCES		
(A) Inventories	8,306.02	9,833.18
(B) Sundry Debtors	6,720.17	5,081.62
(c) Cash and Bank balance	3,251.27	1,300.96
(d) Other current assets		
(e) Loans and Advances	2,063.02	1,711.71
Less: Current Liabilities and Provisions		
(a) Liabilities and provision	3,532.65	3,686.22
Deferred Tax Assets/(Liability) (Net)	(1,150.00)	(1,124.81)
MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)	20.52	47.95
PROFIT AND LOSS ACCOUNT	6,505.74	6,476.75

For MARKSANS PHARMA LIMITED



MARK SALDANHA
Managing Director.



Place: Mumbai.

Date: August 12,2010.

Visit us at www.marksanspharma.com

MARKSANS PHARMA LIMITED

Regd. Office: 21st Floor, Lotus Business Park, Off. New Link Road, Andheri [West], Mumbai-400053

**ANNUAL AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2010 AND
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2010**

Rs.in Lacs

Sr. No.	PARTICULARS	For the Quarter ended on		For the year ended on	For the year ended on
		30.6.2010 (UNAUDITED)	30.6.2009 (UNAUDITED)	31st March 10 (AUDITED)	31st March 09 (AUDITED)
1	Income				
	a>. Net Sales/ Income from Operations	7,204.86	9,656.84	35,936.58	36,013.10
	b>. Other Operating Income	31.14	62.74	183.93	806.40
	Total Income	7,236.00	9,719.58	36,120.51	36,819.50
2	Expenditure				
	a>. Increase/Decrease in stock in trade	(207.62)	(608.30)	1,583.02	(859.69)
	b>. Consumption of Material & Purchases	5,029.87	7,760.24	24,086.08	25,151.46
	c>. Employee Cost	809.99	910.08	3,578.19	3,737.21
	d>. Depreciation	277.37	387.24	1,547.45	1,535.45
	e>. Other Expenditure	778.87	1,269.62	4,325.31	5,819.05
	Total Expenditure	6,688.48	9,718.88	35,120.05	35,383.48
3	Profit from Operations before other income				
	Interest & Exceptional Items (1-2)	547.52	0.70	1,000.46	1,436.02
4	Other Income	-	-	-	-
5	Profit before Interest & Exceptional item (3+4)	547.52	0.70	1,000.46	1,436.02
6	Interest	462.49	538.77	1,923.12	2,135.94
7	Profit after Interest but before Tax Exceptional items	85.03	(538.07)	(922.66)	(699.92)
8	Exceptional items		44.52		
9	Profit/(Loss) from Ordinary activities before Tax (7+8)	85.03	(493.55)	(922.66)	(699.92)
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	2.08	3.38	39.51	95.57
11	Net Profit/(loss) from Ordinary activities after tax(9-10)	82.95	(496.93)	(962.17)	(795.49)
12	Extraordinary Item- Minority Interest	1.94	18.33	42.18	40.05
13	Net Profit/ (Loss) for the period (11-12)	81.01	(515.26)	(1,004.35)	(835.54)
14	Paid up Equity Share Capital (Face Value Re.1 each)	3,678.05	3,678.05	3,678.05	3,678.05
15	Reserve Excluding Revaluation Reserve as per Balance sheet of Previous Accounting year	-	-	-	10,000.66
16	a>. Earnings Per Share (Basic & Diluted) (before extraordinary items.Rs.)	0.02	(0.14)	(0.26)	(0.22)
	b>. Earnings Per Share(Basic & Diluted) (after Extraordinary items- Rs.)	0.02	(0.14)	(0.27)	(0.23)
17	Aggregate of Public Shareholding:				
	- Number of Shares	189,823,694	189,822,361	189,822,361	188,222,361
	- Percentage of Holding	51.61%	51.61%	51.61%	51.17%
18	Promoters and Promoter group Shareholdings	177,983,510	177,983,510	177,983,510	179,583,510
	a>. Pledged/Encumbered				
	- Number of Shares	NIL	NIL	NIL	NIL
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N.A	N.A	N.A	N.A
	- Percentage of Holding (as a % of the total share capital of the Company)	N.A	N.A	N.A	N.A
	a>. Non-encumbered				
	- Number of Shares	177,983,510	177,983,510	177,983,510	179,583,510
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%	100%
	- Percentage of Holding (as a % of the total share capital of the Company)	48.39%	48.39%	48.39%	48.83%

Contd.....2



	For the Quarter ended on		For the year ended on	For the year ended on
	30.6.2010	30.6.2009	31st March 10	31st March 09
Standalone Information	(UNAUDITED)	(UNAUDITED)	(AUDITED)	(AUDITED)
Revenue	4,205.91	4,581.66	20,116.58	21,091.16
Profit Before Tax	120.99	(341.38)	62.67	239.08
Profit After Tax	120.99	(344.76)	28.98	49.50

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12.08.2010.
- There were no pending investor complaints at the beginning and end of the quarter. The Company has not received any investors complaint during the quarter.
- The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- The Consolidated Financial Statements Include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- The Consolidated Financial Statement are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountant of India.
- No Provision have been made during the year for Foreign Exchange Difference account in case of Foreign Currency Convertible Bond. The Management is of the opinion that the determination and crystallisation of liabilities is dependent upon the outcome of uncertain future events or actions, not wholly within the control of the company and therefore the same has been considered as a 'Contingnet Liability' as at 30th June,2010.
- The Company is primarily engaged in a single segment business of Manufacturing & Marketing of Pharmaceutical Formulations and Active Pharmaceutical Ingredients and is managed as one entity, for its various activities and is governed by similar set of risk and returns.
- Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.
- The Company has issued and allotted 1,333 equity shares of R.1 each on conversion of one FCCB of US\$ 1000/- on 14.04.2010. Accordingly, the issued, subscribed and paid up equity share capital of the company has increased from Rs.36,78,05,871/- to Rs.36,78,07,204/- effective from 14.04.2010.
- The company has on 28th July,2010 entered into a Business Transfer Agreement with kores(India) Limited for sale and transfer of its Active Pharmaceutical Ingredients (API) business together with its Manufacturing facilities located at plot Nos.A-88 and D-10,MIDC, Kurkumbh, Pune, Maharashtra.
- The variation in Profit Before Tax is due to Amortisation of Goodwill,Intangible Assets and Interest in the Books of Marksans Pharma (U.K.) Ltd. during F.Y.2009-10.
- Statement of Assets and Liabilities.

(Rs. In Lakhs)

Particulars	YEAR ENDED	YEAR ENDED
	31.03.2010	31.03.2009
	AUDITED	AUDITED
SHAREHOLDERS FUND:		
(a) Capital	5,028.06	5,028.06
(b) Reserve and Surplus	6,513.46	4,428.34
LOAN FUNDS	42,402.72	39,653.67
Minority Interest	91.38	69.01
FIXED ASSETS	39,171.98	38,046.47
INVESTMENTS	1,000.00	-
CURRENT ASSETS, LOANS AND ADVANCES		
(A) Inventories	10,452.25	11,907.99
(B) Sundry Debtors	9,471.78	10,168.16
(c) Cash and Bank balance	3,550.07	2,234.38
(d) Other current assets		
(e) Loans and Advances	2,112.50	1,754.75
Less: Current Liabilities and Provisions		
(a) Liabilities and provision	5,954.63	8,212.44
Deferred Tax Assets/(Liability) (Net)	(1,220.87)	(1,195.87)
MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OF	20.52	47.95
PROFIT AND LOSS ACCOUNT	4,567.98	5,572.32

For MARKSANS PHARMA LIMITED

Place: Mumbai.
Date: August 12,2010
Visit us at www.marksanspharma.com

MARK SALDANHA
Managing Director.

